Directorio

In this study, everyone receives a medicine called EVOLVE104 through an IV, which means it goes into a vein. This is an open label study, so everyone knows the drug and dose they are getting. Each infusion takes about one hour, and doctors will watch you closely during the infusion and for up to two days after it, especially at the beginning. The first three doses are given one week apart. After that, the doses are given every week or every two weeks in 28 day cycles. Early doses may require staying in the hospital overnight and may start at a lower amount that increases slowly to help your body adjust. During the study, you will have regular checkups, blood tests, heart tests, scans every eight weeks, and eye exams. The study has different stages, including screening, treatment, end of treatment, and long term follow up. Screening can last up to 28 days and includes exams, blood tests, heart tests, eye exams, and scans to make sure you can join the study.

We are doing this study to find out if an experimental drug called XC001 (the study drug) is an effective option for people who have angina that is caused by coronary artery disease. We want to know if the study drug can provide relief when common, approved therapies have failed to do so. The study drug is made using an adenovirus (one of the causes of the common cold). The adenovirus in the study drug is genetically altered so it is able to deliver a protein called VEGF (vascular endothelial growth factor) to the heart and potentially spur the growth of new blood vessels.

In this study, people will get a new kind of eye transplant. They'll be randomly chosen (like flipping a coin) to get either a special treated cornea or a regular one. Doctors will check on them for 2 years after the transplant to see how they're doing and to watch for any side effects.

In this study, people will be placed into one of three groups by chance. One group will receive a medicine called zanzalintinib by mouth every day and another medicine called MK 3475A as an injection every three weeks. A second group will receive only zanzalintinib each day. The third group will receive a placebo pill that looks like zanzalintinib but has no active medicine. People in the second and third groups will not know which one they are receiving. During the study, participants will have regular clinic visits and medical tests to check their health and how well the treatment is working. The study medicine may be given for up to two years, and participants may be followed for up to five years so researchers can continue to monitor their health and study results.

This study is about helping astronauts stay safe during moonwalks. When astronauts go to the moon, they wear special suits with lower air pressure, which can cause small bubbles to form in the body. These bubbles can cause a problem called decompression sickness, which may lead to pain or weakness. To help prevent this, astronauts breathe pure oxygen before their moonwalk. In this study, people will breathe oxygen for about one hour while resting or doing different levels of exercise. After that, they will enter a special room that lowers air pressure to feel like being in a spacesuit. While inside, they will do light exercises and have ultrasound tests to look for bubbles in the body. This part lasts about six hours. The goal is to learn how well oxygen breathing and activity help prevent decompression sickness.